Alphacait

Alphacait is a biotechnology company specializing in the development of targeted nanotherapeutics and drug screening platforms for oncology. The company's foundational technology, licensed from the University of California, Davis, focuses on a novel ligand that targets leukemia stem cells to enhance the efficacy of treatments for human leukemia. Additionally, Alphacait employs a proprietary screening system to identify and evaluate drug combinations for advanced solid tumors and non-small cell lung cancer. With operations in both the United States and China, the company collaborates with partners like Haining Health-Coming Biotech to advance its clinical programs. The company's approach combines precision targeting with advanced nanomedicine to address unmet needs in hematologic and solid malignancies.